Speaker illustration

Professor Faiez Zannad

University of Lorraine, Vandoeuvre-Les-Nancy (France)

Member of:

European Society of Cardiology

MD, PhD, Cardiologist, Clinical pharmacologist. Trained at Université de Lorraine, Université of Lyon, France and Medical Research Council (Oxford, UK). Currently, Emeritus Professor of Therapeutics at Université de Lorraine, France. As a trialist, he contributed to building the evidence supporting modern HF therapy, notably with beta-blockers, RAASi and MRAs. As a clinical scientist his work focuses on fibrosis and biomarkers. He has served as Chairman of the French Society of Hypertension, of the ESC Working Group on Pharmacology and Drug Therapy. He is the founder of the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop with meetings in Paris, Washington DC, in Asia and the Middle East. Professor Zannad published more than 750 peer-reviewed papers. He received the 2014 European Society of Hypertension Paul Milliez Award and the 2017 Lifetime Achievement Award from the ESC-HFA and served as an Eugene Braunwald Scholar in 2019 at Harvard Medical School.

What's next for your patients following a worsening HF event?

Event: ESC Congress 2021 - The Digital Experience

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session type: Satellite Symposium

Thumbnail

Empagliflozin across the spectrum of ejection fraction in HF ‒ aggregate findings from the EMPEROR programme

Event: ESC Congress 2021 - The Digital Experience

Topic: Chronic Heart Failure

Session type: Satellite Symposium

Thumbnail

Neuromodulation for the management of patients with HFrEF: the present and the future

Event: ESC Congress 2021 - The Digital Experience

Topic: Chronic Heart Failure

Session type: Satellite Symposium

Thumbnail

Unleashing the full potential of SGLT2 inhibition in heart failure: optimizing patient benefit in clinical practice

Event: Heart Failure 2021 Online Congress

Topic: Heart Failure

Session type: Satellite Symposium

Thumbnail

New approach for worsening chronic heart failure

Event: ESC CONGRESS 2019

Topic: Chronic Heart Failure

Session type: Satellite Symposium

Thumbnail

Could neuromodulation via the baroreflex work in heart failure after all?

Event: ESC CONGRESS 2019

Topic: Treatment

Session type: Satellite Symposium

Thumbnail

Know it by heart – New opportunities for cardiologists in the Sodium-Glucose-Co-Transporter 2 (SGLT2) inhibitor era

Event: Heart Failure 2019 - 6th World Congress on Acute Heart Failure

Topic: Diabetes and the Heart

Session type: Satellite Symposium

Thumbnail

Emerging therapies in heart failure

Event: Heart Failure 2019 - 6th World Congress on Acute Heart Failure

Topic: Pathophysiology

Session type: Symposium

Thumbnail

Management of hyperkalaemia in patients with heart failure – Overcoming barriers to optimal renin-angiotensin-aldosterone system inhibitor therapy

Event: Heart Failure 2019 - 6th World Congress on Acute Heart Failure

Topic: Comorbidities

Session type: Satellite Symposium

Thumbnail

New directions in the management of thrombotic risks in patients with heart failure

Event: ESC Congress 2018

Topic: Chronic Heart Failure

Session type: Satellite Symposium

Thumbnail

This platform is supported by

logo Novo Nordisk